scholarly journals Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Catherine W. Saltus ◽  
Zdravko P. Vassilev ◽  
Jihong Zong ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Cohort Study ◽  
Incidence Rate ◽  
Retrospective Cohort ◽  
Population Based ◽  
Second Primary ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Second Primary Malignancies

Background. New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We also estimated the proportion of men with CRPC with bone metastases and overall survival. Methods. We conducted a retrospective cohort study of United States (US) men aged ≥ 65 years with CRPC. Cohort entry was from January 1, 2000, to December 31, 2011, with follow-up through December 31, 2013. Castration resistance was defined by treatment with second-line systemic therapy (after surgical or medical castration). SPM were diagnoses of primary cancers (other than prostate) in SEER or Medicare data. Results. Altogether 2,234 patients met eligibility criteria. Most (1,887; 84.5%) had evidence of bone metastases in Medicare claims. SPM occurred in 172 patients (incidence rate 5.9 per 100 person-years; 95% confidence interval [CI], 5.0-6.8; standardized incidence ratio = 3.1, 95% CI, 2.8-3.6, based on SEER incidence rate of all malignancies except prostate cancer among men aged ≥ 65 years). The most common SPM were lung/bronchus (n = 29, 16.9%), urinary bladder (n = 22, 12.8%), and colon/rectum (n = 21, 12.2%). Median survival was 1.2 years (95% CI, 1.1-1.3); 5-year survival was 9% (95% CI, 7-11%). Conclusions. This study provides the first estimate of SPM risk in older men with CRPC in the US. The incidence rate is approximately threefold higher than the population-based cancer incidence among men without prostate cancer.

scholarly journals Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries

2020 ◽  
Vol 16 (25) ◽  
pp. 1889-1901
Author(s):  
Zdravko P Vassilev ◽  
Montse Soriano Gabarró ◽  
James A Kaye ◽  
Catherine W Saltus ◽  
Oliver Riedel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Claims Data ◽  
Second Primary ◽  
Research Database ◽  
Castration Resistant Prostate Cancer ◽  
Cancer Data ◽  
Castration Resistant ◽  
The Us ◽  
Second Primary Malignancies ◽  
Medicare Database

Aim: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Patients & methods: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. Results: SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4–88.4), 101.7 (95% CI: 90.3–114.5) and 59 (95% CI: 50–68) per 1000 person-years in German, Swedish and US cohorts, respectively. Conclusion: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.

Castration resistance and risk of bone metastases among men with nonmetastatic prostate cancer on androgen-deprivation therapy: A population-based cohort study from the Henry Ford Health System (HFHS) in Detroit, Michigan.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 163-163
Author(s):  
Jennifer Beebe-Dimmer ◽  
Karynsa Cetin ◽  
Cecilia Yee ◽  
Scott Stryker ◽  
Lois Lamerato ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
High Risk ◽  
Bone Metastases ◽  
Androgen Deprivation Therapy ◽  
Population Based ◽  
Androgen Deprivation ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Increased Risk

163 Background: Androgen deprivation therapy (ADT) is the cornerstone treatment of metastatic prostate cancer (PC), but is frequently used in the non-metastatic (M0) setting. After a variable period of hormone sensitivity, most patients develop castration-resistant prostate cancer (CRPC). These men are at increased risk of developing bone metastases (BM), particularly in those with higher serum PSA and shorter PSA doubling time (DT). The epidemiology and natural history of M0 CRPC has not been well studied in a population-based setting. Methods: Using HFHS patient records, a retrospective cohort study was conducted among 723 men diagnosed with M0 PC between 1996 and 2005 (with follow-up [f/u] for outcomes through 12/31/2008), who received ADT, including 613 men with serial PSA measurements for CRPC determination. CRPC was defined as 2 consecutive PSA rises, with “high-risk” defined as PSA ≥ 8 ng/mL or PSA DT ≤ 10 months (mos) after the development of CRPC. The risk of subsequent BM was estimated for the overall cohort and for the CRPC and non-CRPC subsets. Results: The median age among patients in the study was 73 years, 48% were African American, and median f/u time after ADT initiation was 58 mos. 15% (n=93) met criteria for CRPC during f/u (with a median of 23 mos between ADT initiation and establishment of CRPC), with the majority considered being at high risk (n=81). Among the entire cohort, 74 men (10%) developed BM during f/u. The rate of BM was 4 times higher among CRPC patients compared to non-CRPC patients (p<0.001), with a median of 6 mos between CRPC and subsequent BM. No racial difference was observed with either the incidence of CRPC or BM. Conclusions: The HFHS resource allowed for investigation of disease progression in a racially diverse population. A substantial proportion of M0 PC patients on ADT will eventually develop CRPC and once castration-resistant, risk of BM is high.

scholarly journals Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0175217 ◽  
Author(s):  
Chao-Yueh Fan ◽  
Wen-Yen Huang ◽  
Chun-Shu Lin ◽  
Yu-Fu Su ◽  
Cheng-Hsiang Lo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancies
Sign in / Sign up

Export Citation Format

Share Document